Leerink Partnrs Issues Optimistic Forecast for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.39). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals' Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.67) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. During the same period in the prior year, the firm posted ($0.54) earnings per share. The firm's quarterly revenue was up 61.2% on a year-over-year basis.

Several other equities analysts also recently commented on MIRM. HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. JMP Securities increased their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday. Robert W. Baird boosted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Finally, Raymond James raised their target price on shares of Mirum Pharmaceuticals from $73.00 to $77.00 and gave the stock a "strong-buy" rating in a research note on Tuesday. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $60.64.

Mirum Pharmaceuticals Trading Down 0.7%

MIRM traded down $0.30 during mid-day trading on Monday, hitting $45.27. 422,516 shares of the stock were exchanged, compared to its average volume of 525,600. Mirum Pharmaceuticals has a 1-year low of $23.83 and a 1-year high of $54.23. The firm's fifty day moving average is $42.84 and its two-hundred day moving average is $44.34. The company has a market cap of $2.24 billion, a PE ratio of -22.41 and a beta of 0.95. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Insiders Place Their Bets

In other news, Director Patrick J. Heron purchased 1,335 shares of the stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $45.57 per share, for a total transaction of $60,835.95. Following the acquisition, the director now owns 163,643 shares of the company's stock, valued at $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jolanda Howe sold 57,606 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,764 shares of company stock worth $4,109,161 in the last 90 days. 14.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MIRM. Fox Run Management L.L.C. acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at about $707,000. E Fund Management Co. Ltd. bought a new stake in Mirum Pharmaceuticals in the first quarter worth approximately $218,000. Russell Investments Group Ltd. raised its stake in shares of Mirum Pharmaceuticals by 783.9% in the 1st quarter. Russell Investments Group Ltd. now owns 229,449 shares of the company's stock valued at $10,337,000 after acquiring an additional 203,489 shares in the last quarter. Nuveen LLC bought a new stake in shares of Mirum Pharmaceuticals during the 1st quarter worth $29,495,000. Finally, Aigen Investment Management LP boosted its holdings in Mirum Pharmaceuticals by 28.2% during the first quarter. Aigen Investment Management LP now owns 9,929 shares of the company's stock valued at $447,000 after acquiring an additional 2,187 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.